Clinical Trial Update: A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia [Phase 3]

View source ↗

Summary

Astellas reports completion of a Phase 3 study evaluating intermittent oral dosing of ASP1517 in non-dialysis chronic kidney disease patients with anemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• ASP1517

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Chronic Kidney Disease | Phase 3 | Status: COMPLETED